- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S8651
| Related Targets | PI3K Akt mTOR GSK-3 ATM/ATR DNA-PK AMPK PDPK1 PP2A PDK |
|---|---|
| Other PTEN Products | SF1670 VO-Ohpic trihydrate Phospho-PTEN (Ser380/Thr382/383) Antibody [K19C17] Phospho-PTEN (Thr366) Antibody [A11K14] PTEN Antibody [J22G2] |
|
In vitro |
Water : 69 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 347.24 | Formula | C6H4NO8V.2K |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 722494-26-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Bisperoxovanadium (HOpic) | Smiles | [K+].[K+].OC1=CC=C2N(=C1)|[V+3]|3|4(|[O-][O-]|3)(|[O-][O-]|4)(|[O-]C2=O)=O | ||
| Targets/IC50/Ki |
PTEN
(Cell-free assay) 14 nM
|
|---|---|
| In vitro |
Treatment with 1 μM BpV(HOpic) is capable of increasing the in vitro migration of C2C12 myoblasts without significantly reducing their ability to differentiate and fuse into multinucleated myotubes. This compound enhances AKT and ERK1/2 signaling, which is in conjunction with its effects on myoblast migration.
|
| In vivo |
Compared with vehicle-treated mice with IRI (renal ischemia/reperfusion injury), pharmacological inhibition of PTEN with bpV (HOpic) exacerbates renal dysfunction and promotes tubular damage. PTEN inhibition with this compound enhances tubular cell apoptosis in kidneys with IRI, which is associated with excessive caspase-3 activation. Furthermore, it expands the infiltration of neutrophils and macrophages into kidneys with IRI, which is accompanied by increased expression of the proinflammatory molecules.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.